

Figure S1. The overall survival for TMZ treated patients with *MGMT* methylated or unmethylated GBM.

A-B. Kaplan–Meier survival curves for TMZ treated GBM patients stratified by the *MGMT* methylation status in the training set (A) and the validation set (B), respectively.




Figure S2. Relationship between the risk score and clinicopathological features of TMZ treated *MGMT* un-methylated GBM.

A-D Distribution of risk scores in the TMZ treated *MGMT* unmethylated GBM stratified by Age (A), Gender (B), Chromosome 7 gain and Chromosome 10 loss status (C), and TCGA defined subtypes (D).




Figure S3. Relationship between the risk score and the clinicopathological features of all GBM. A-D Distribution of risk scores in the GBM by Age (A), Gender (B), IDH status (C), MGMT promoter methylation status (D), Chromosome 7 gain and Chromosome 10 loss status (E), with or without TMZ (F), and TCGA defined subtypes (G).